The Microfluidics team was excited to participate as joint presenters, with leaders from Biotest and Research Center Pharmaceutical Engineering (RCPE), on our recent webinar.
The topic of the webinar discussed:
Comparison of Biotest HSA and Recombinant HSA for the Preparation of Nano Albumin Bound (nab) Paclitaxel using Microfluidizer® Technology.
This session presented nab-paclitaxel technologies produced with the use of a high shear Microfluidizer® processor.
Nanoparticle albumin bound (nab) technology is an important carrier for delivering low-aqueous solubility, high-toxicity therapeutic agents with fewer side effects than traditional systems, which makes it ideally suited for use in chemotherapy medication.
Our distinguished speakers included:
Dr. Liye Maeyama
As Biotest AG's Global Product Manager, Dr. Liye Maeyama is currently focused on the assessment of various characteristics of albumin (for example redox state of Cysteine 34, binding characteristics, purity) and its effect on albumin excipient application in nanoencapsulation, and in induced pluripotent stem cells. Dr. Liye Maeyama earned a Ph. D. in Biochemistry from Cologne University (Germany).
Dr. Carolin Tetyczka
Since August 2021, Dr. Carolin Tetyczka has been a Senior Scientist at the Research Center Pharmaceutical Engineering (RCPE) focusing on manufacturing and characterization of nano drug delivery systems. Dr. Tetyczka holds a Ph. D. with her thesis titled, “(Bio)pharmaceutical investigations of nano drug delivery systems.” Dr. Tetyczka holds a diploma in pharmacy from the University of Graz.
Matt Laferriere
As a Microfluidics’ Applications Engineer, Matt Laferriere has an in-depth understanding of a wide variety of applications, including nanoemulsions, cell disruption and nanoparticles. During his tenure, Matt has amassed extensive knowledge performing proof of concept, process optimization, and scale-up tests at the Westwood, MA facility. Matt earned a Bachelor of Science in Chemical Engineering and a Minor in Mathematics and Nuclear Engineering from the University of Rhode Island.
Topics included in this discussion are:
In this session, the processability and properties of nab-Paclitaxel using Biotest HSA in comparison to a commercially available recombinant HSA was presented. In addition, quality parameters including content of small peptides, fatty acids, aggregates, binding characteristics of site II and the redox state in terms of cysteine-34 of Biotest HSA and other commercially available HSA solutions was discussed.
- Exploration of the processability and properties of nab Paclitaxel using Biotest HSA
- Comparison of Biotest HSA to commercially available recombinant HSA.
- Manufacturing considerations for Nab Paclitaxel (such as cGMP requirements, repeatability and scalability)
Related reading:
- Nanoparticle Albumin Bound technology for nab-paclitaxel production
- How does Microfluidizer technology support vaccine development FAQ
- Creating an effective nab-paclitaxel drug delivery system
- Manufacturing Drug Delivery Systems
- Application Note - Microfluidizer® Technology for scalable production of Nab-Paclitaxel
Posted by
Cathy SilvaTopics:
Nab Drug Delivery